Abstract：Objective To investigate the radiosensitizing effect of 3-(5′-hydroxy-2′-furyl)-1-benzyl indazole (YC-1) on hypoxic human adenocarcinoma cell line A549. Methods MTT assay was used to test the inhibitory effect of YC-1 on proliferation of A549 cells. Clonogenic assay was performed to determine the radiosensitizing effect of YC-1 on hopxic A549 cells. Single-hit multi-target model was used to plot survival curve and calculate sensitization enhancement ratio (SER). The cell cycle and apoptosis were measured by flow cytometry. Results The proliferation of A549 cells was inhibited by YC-1 in a time-dose-dependent manner. In normoxic and hypoxic cells, the IC20 was 16.7 μmol/L and 39.2 μmol/L at 24 h, respectively. In the group of hypoxia plus YC-1,SERD0 and SERDq were 1.11 and 1.26, respectively. In hypoxia, YC-1 combined with 2 Gy irradiation could induce cell apoptosis and prolong G2+M phase arrest ((30.17±1.21)%∶(15.44±0.96)%, P=0.000;(21.56±0.47)%∶(6.16±0.16)%,P=0.000). ConclusionsYC-1 could enhance the radiosensitivity of hypoxic A549 cells.
CNEN Qin*,QIAO Yun,DAI Peng et al. Effect of YC-1 on improving hypoxia and radiosensitizing human lung adenocarcinoma cells in vitro[J]. Chinese Journal of Radiation Oncology, 2012, 21(4): 396-399.
[1] Vaupel P, Mayer A．Hypoxia in cancer:significance and impact on clinical outcome．Cancer Metast Rev,2007,26:225-239． [2] Toma-Dasu L, Dasu A, Karlsson M．The relationship between temporal variation of hypoxia, polarographic measurements and predictions of turnour response to radiation．Phys Med Biol,2004,49:4463-4475． [3] Piret JP, Mottet D, Raes M, et al．COCl2,a chemical inducer of hypoxia inducible factor-1,and hypoxia reduce apoptotic cell death in hepatoma cell line HepG2．Ann N Y Acad Sci,2002,973:443-447． [4] Brown JM, Giaccia AJ. The unique physiology of solid tumors:opportunities (and problems) for cancer therapy. Cancer Res,1998,58:1408-1416. [5] Postovit LM, Adams MA, Lash GE,et al．Oxygen-mediated regulation of tumor cell invasiveness. Involvement of a nitric oxide siginaling pathway. J Biol Chem,2002,277:35730-35737. [6] Yeo EJ, Chun YS, Cho YS, et al. YC-1:a potential anticancer drug targeting hypoxia-inducible factor 1.J Natl Cancer Inst,2003,95:516-525. [7] Pan SL, Guh JH, Peng CY, et al. YC-1[3-(5′-Hydroxymethyl-2′-furyl)-l-benzylindazole]inhabits ndothelial cell functions induced by angiogenic factors in vitro and angiogensis in vivo models. J Pharmacol Exp Ther,2005,314:35-42. [8] Wang SW, Pan SL, Guh JH, et al. YC-1[3-(5′-Hydroxymethyl-2′-furyl)-l-benzylindazole]exhibits a novel antiproliferative effect and arrests the cell cycle in G0-G1 in human hepatocellular carcinoma cells. J Pharmacol Exp Ther,2005,312:917-925. [9] Huang YT, Pan SL, Guh JH, et al. YC-1 suppresses constitutive nuclear factor-kappa B activation and induces apoptosis in human prostate cancer cells. Mol Cancer Ther,2005,4:1628-1635. [10] Chun YS, Yeo EJ, Park JW. Versatile pharmacological actionsof YC-1:anti-platelet to anticancer. Cancer Lett,2004,207:1-7. [11] Chun YS, Yeo EJ, Choi E, et al. Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol,2001,61:947-954.
2012, Vol. 21 
